Skip to main content

Table 1 Characteristics of HIV Subgroups

From: Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study

Characteristic EI-AED NEI-AED Non-AED EI-AED vs.
NEI-AED
(p-values)
EI-AED vs.
Non-AED
(p-values)
Number, n 19 85 190   
Demographics (n, % or mean ± SD)      
   Age at HIV diagnosis (y) 30.2 ± 10.0 32.5 ± 8.9 30.0 ± 7.9 0.331 0.912
   Age at first HAART/AED overlap or index HAART (y) 40.1 ± 8.7 45.1 ± 9.0 38.7 ± 9.1 0.027 0.522
   Female 1 (5.3) 13 (15.3) 18 (9.5) 0.249 0.544
   Race/ethnicity     0.323 0.137
European American 13 (68.4) 46 (54.1) 89 (46.8)   
African American 6 (31.6) 32 (37.6) 84 (44.2)   
Other 0 (0.0) 7 (8.2) 17 (8.9)   
   Year of HIV diagnosis (median, range) 1988 (1985 - 2000) 1990 (1986 - 1999) 1990 (1985 - 2000) 0.145 0.122
   CD4+ at HIV diagnosis (cells/uL) 632 ± 398 525 ± 321 483 ± 235 0.340 0.068
   CD4+ at first HAART/AED overlap or index HAART (cells/uL) 310 ± 290 380 ± 247 364 ± 232 0.329 0.392
   Viral load (log10) at first HAART/AED overlap or index HAART (copies/mL) 3.8 ± 1.6 3.1 ± 1.4 3.6 ± 1.4 0.075 0.572
   AIDS-defining event prior to first HAART/AED overlap or index HAART 11 (57.9) 35 (41.2) 40 (21.1) 0.187 <.001
HAART regimen at first HAART/AED overlap or index HAART (n, %)     0.189 0.543
   PI-based 12 (63.2) 35 (41.2) 117 (61.6)   
   NNRTI-based 5 (26.3) 29 (34.1) 36 (18.9)   
   PI + NNRTI 2 (10.5) 21 (24.7) 37 (19.5)   
Number of HAART/AED overlap periods (n, %)     0.343 ---
   1 7 (36.8) 47 (55.3) ---   
   2 5 (26.3) 17 (20.0) ---   
   ≥ 3 7 (36.8) 21 (24.7) ---   
Months of HAART/AED overlap (median, range)      
   First overlap period 7.0 (1.0 - 96.4) 9.1 (1.3 - 65.4) --- 0.231 ---
   All overlap periods 21.3 (1.0 - 155.4) 22.1 (1.6 - 120.3) --- 0.798 ---
Year of first HAART/AED overlap or index HAART (median, range) 1998 (1996 - 2006) 2003 (1996 - 2009) 1998 (1996 - 2006) 0.002 1.000
HAART use prior to first HAART/AED overlap or index HAART (n, %)     0.010 0.523
   No prior HAART 4 (21.1) 6 (7.1) 40 (21.1)   
   <1 year 4 (21.1) 7 (8.2) 37 (19.5)   
   1-2 years 2 (10.5) 7 (8.2) 31 (16.3)   
   2-3 years 4 (21.1) 6 (7.1) 17 (8.9)   
   >3 years 5 (26.3) 59 (69.4) 65 (34.2)   
Duration of first HAART/AED overlap or index HAART (n, %)     0.144 0.495
   <1 year 10 (52.6) 22 (25.9) 69 (36.3)   
   1-2 years 4 (21.1) 22 (25.9) 63 (33.2)   
   2-3 years 2 (10.5) 15 (17.6) 31 (16.3)   
   >3 years 3 (15.8) 26 (30.6) 27 (14.2)   
  1. EI-AED, enzyme-inducing antiepileptics (phenytoin, carbamazepine, phenobarbital); NEI-AED, antiepileptics that are not enzyme-inducing; Non-AED, subgroup of all subjects in the cohort (exclusive of other groups) matched according to year of HAART start and number of previous HAART regimens; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor